FOS and glioblastoma: In contrast, the treatment with the Top2β antagonist ICRF193 decreased the mean expression of cFos significantly to 37 ± 3% in the G1702 cells (p < 0.001), underlining the striking importance of the Top2β on cFos expression in GBM cells.